Apoptosis: the importance of nuclear medicine

Nuclear Medicine Communications

Volumn 21, Issue 3, 2000, Pages 241-250

  Blankenberg, F G ^a   Tait, J ^a   Ohtsuki, K ^b   Strauss, H W ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; LIPOCORTIN 5; RADIOPHARMACEUTICAL AGENT;

ANIMAL; APOPTOSIS; HUMAN; NUCLEAR MEDICINE; PHYSIOLOGY; REVIEW;

ANIMALS; ANNEXIN A5; APOPTOSIS; HUMANS; NUCLEAR MEDICINE; RADIOPHARMACEUTICALS;

EID: 0034150727     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200003000-00008     Document Type: Article

References (52)

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-257.
2. Thompson BC. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-1462.
3. Du C, Hu R, Csernasky CA, Hsu CY, Choi DW. Very delayed infarction after mild focal cerebral ischemia: A role for apoptosis? J Cereb Blood Flow Metab 1996; 16: 195-201.
4. Narula J, Haider N, Vimani R et al. Apoptosis in myocytes in end-stage heart failure. New Engl J Med 1996; 335: 1182-1189.
5. Kageyama Y, Li X-K, Suzuki S et al. Apoptosis is involved in acute cardiac allograft rejection in rats. Ann Thorac Surg 1998; 65: 1604-1609.
6. Lennon SV, Martin SJ, Cotter TG. Dose-dependent induction of apoptosis in human tumor cell lines by widely diverging stimuli. Cell Prolif 1991; 24: 203-214.
7. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-1456.
8. Dong C, Wilson JE, Winters GL, McManus BM. Human transplant coronary artery disease: Pathological evidence for Fas-mediated apoptotic cytotoxicity in allograft arteriopathy. Lab Invest 1996; 74: 921-931.
9. Yaoita H, Ogawa K, Maehara K, Maruyama Y. Attenuation of ischemia/reperfusion injury in rats by caspase inhibitor. Circulation 1998; 97: 276-281.
10. Hara H, Friedlander RM, Gagliardini V et al. Inhibition of interleukin 1β-converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage. Proc Natl Acad Sci USA 1997; 94: 2007-2012.
11. Blankenberg FG, Katsikis PF, Tait JF et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA 1998; 95: 6349-6354.
12. Blankenberg FG, Katsikis PD, Tait JF et al. Imaging of apoptosis (programmed cell death) with technetium 99m annexin V. J Nucl Med 1999; 40: 184-191.
13. Vriens PW, Blankenberg FG, Stoot JH et al. The use of technetium labeled annexin V for in vivo imaging of apoptosis during cardiac allograft rejection. J Thorac Cardiovasc Surg 1998; 116: 844-853.
14. Van Engeland M, Nieland LJW, Ramaekers FCS, Schutte B, Reutelingsperger CPM. Annexin V-affinity assay: A review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 1998; 31: 1-9.
15. Martin SJ, Reutelingsperger CPM, McGahon AJ. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl 2 and Abl. J Exp Med 1995; 182: 1545-1556.
16. Allen RT, Hunter III WJ, Agrawal DK. Morphological and biochemistry characterization and analysis of apoptosis. J Pharmacol Toxicol Meth 1997; 37: 215-228.
17. Steller H. Mechanisms and genes of cellular suicide. Science 1995; 267: 1445-1449.
18. Darzynkiewicz Z. Apoptosis in antitumor strategies: Modulation of cell cycle or differentiation. J Cell Biochem 1995; 58: 151-159.
19. Ogasawara J, Watanabe-Fukunaga R, Adachi M. Lethal effects of anti-Fas antibody in mice. Nature 1993; 364: 806-809.
20. Thornberry NA, Lazenbnik Y. Caspases: Enemies within. Science 1998; 281: 1312-1316.
21. Rodriguez I, Matsuura K, Ody C, Nagata S, Vassalli P. Systemic injection of tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death. J Exp Med 1996: 184: 2067-2072.
22. Hasegawa JIS, Kamiike W, Shimizu S, Imazu T, Matsuda H, Tsujimoto Y. Involvement of CPP32/Yama (-like) proteases in fas-mediated apoptosis. Cancer Res 1996; 56: 1713-1718.
23. Jaeschke H, Fisher MA, Lawson JA, Simmons CA, Farhood A, Jones DA. Activation of caspase 3 (CPP32)-like protreases is essential for TNF-α induced hepatic parenchymal cell apoptosis and neutrophil-mediated necrosis in a murine endotoxin shock model. J Immunol 1998; 160: 3480-3486.
24. Zwaal RFA, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997; 89: 1121-1132.
25. Boersma AWM, Kees N, Oostrum RG, Stoter G. Quantification of apoptotic cells with fluorescein isothiocynate-labeled annexin V in Chinese hamster ovary cell cultures treated with cisplatin. Cytometry 1996; 24: 121-130.
26. Bennett MR, Gibson DR, Schwartz SM, Tait JF. Binding and phagocytosis of apoptotic vascular smooth muscle cells is mediated in part by exposure of phosphatidylserine. Circ Res 1995; 77: 1136-1142.
27. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309-1312.
28. Fan T, Lu H, Hu H et al. Inhibition of apoptosis in Chlamydia-infected cells: Blockade of mitochondrial cytochrome c release and caspase activation. J Exp Med 1998; 187: 487-496.
29. Tepper CG, Studzinski GP. Resistance of mitochondrial DNA to degradation characterizes the apoptotic but not the necrotic mode of leukemia cell death. J Cell Biochem 1993; 42: 352-361.
30. Leist M, Single B, Castoldi AF, Kuhnle S, Nicotera P. Intracellular adenosine triphosphate (ATP) concentration: A switch in the decision between apoptosis and necrosis. J Exp Med 1997; 185: 1481-1486.
31. Mantiba B, Mariani SM, Krammer PH. The CD95 system and the death of a lymphocyte. Immunology 1997; 9: 59-68.
32. Schultz M, Schuerman HJ, Joergensen J et al. Acute rejection of vascular heart allografts by perforin deficient mice. Eur J Immunol 1995; 25: 474-480.
33. Naito M, Nagashima K, Mashima T, Tsuruo T. Phosphatidylserine externalization is a downstream event of interleuken-1β-converting enzyme family protease activation during apoptosis. Blood 1997; 89: 2060-2066.
34. Kojima H, Endo K, Moriyama H et al. Abrogation of a cytochrome c release and caspase-3 activation in acquired multidrug resistance. J Biol Chem 1998; 273: 16647-16650.
35. Van Heerde WL, de Groot PG, Reutelingsperger CPM. The complexity of the phospholipid binding protein annexin V. Thrombosis and Haemostasis 1995; 73: 172-179.
36. Wood BL, Gibson DF, Tait JF. Increased phosphatidylserine exposure in sickle cell disease: Flow-cytometric measurement and clinical association. Blood 1996; 88: 1873-1880.
37. Tait JF, Gibson D. Measurements of membrane phospholipid asymmetry in normal and sickle-cell erythrocytes by means of annexin V binding. J Lab Clin Med 1994; 123: 741-748.
38. O'Brien IEW, Reutelingsperger CPM, Holdaway KM. Annexin V and TUNEL use in monitoring the progression of apoptosis in plants. Cytometry 1997; 29: 28-33.
39. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger CPM. A novel assay for apoptosis flow cytometry detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled annexin V. J Immunol Meth 1995; 184: 39-51.
40. Van den Eijnde SM, Luijsterburg AJM, Boshart L et al. In situ detection of apoptosis during embryogenesis with annexin V: From whole mount to ultrastructure. Cytometry 1997; 29: 313-320.
41. Koopman G, Reutelingsperger CPM, Kuitjten GAM, Keehnen RMJ, Pals ST, van Oers MJH. Annexin V for flow cytometric detection of phosphatidylserine expression of B cells undergoing apoptosis. Blood 1994; 84: 1415-1420.
42. Reutelingsperger CPM, van Heerde WL. Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell Mode Life Sci 1997; 53: 527-532.
43. Tait JF, Cerqueira MD, Dewhurst TA. Evaluation of annexin V as a platelet-directed thrombus targeting agent. Thrombosis Res 1994; 75: 491-501.
44. Statton, JR, Dewhurst TA, Kasina S et al. Selective uptake of radiolabeled annexin V on acute porcine left atrial thrombi. Circulation 1995; 92: 3113-3121.
45. Abrams MJ, Juweid M, Tenkate CI. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazinonicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 1990; 31: 2022-2028.
46. Larsen SK, Solomon HF, Caldwell G, Abrams MJ. [99mTc] tricine: A useful precursor complex for radiolabeling of hydrazinonicotinamide protein conjugates. Bioconj Chem 1995; 6: 535-538.
47. 99mTc-HYNIC annexin V: A radiopharmaceutical for the in vivo detection of apoptosis. Eur J Nucl Med (in press).
48. Ogura Y, Blankenberg FG, Martinez OM et al. Detection of liver allograft apoptosis using an in vivo imaging technique. Transplantation (in press).
49. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 439-501.
50. Blankenberg FG, Busch E, Yenari MA et al. In vivo imaging of apoptotic cell death associated with cerebral hemispheric ischemia using 99mTc radiolabeled annexin V (abstract). Stroke 1998; 29: 330.
51. Blankenberg FG, Naumovski L, Strauss HW. Imaging normal and chemotherapeutically treated hematopoietic bone marrow using radiolabeled annexin V (abstract). Pedatr Radiol (in press).
52. Lamb JR, Friend SH. Which guesstimate is the best guesstimate? Predicting chemotherapeutic outcomes. Nat Med 1997; 3: 962-963.